PRODUCT LITERATURE

Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity programme

---

Ageing may affect drug efficacy and safety in patients with heart failure (HF). The Candesartan in Heart ailureAssessment of Reduction in Mortality and morbidity (CHARM) programme offered an opportunity to study the relationship between increasing age and the efficacy and safety of treatment in an uniquely broad spectrum of patients with symptomatic HF and either reduced or preserved left ventricular ejection fraction.

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Canderin

Specific Detail Info

European Heart Journal (2008) 29, 3022–3028

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment